Eisai / Biogen’s Leqembi is set to capitalize on the unfulfilled potential for a disease-modifying therapy (DMT) for Alzheimer’s disease (AD), and additional anti-Aβ monoclonal antibodies (MAbs) (e.g., Eli Lilly’s donanemab) will drive competition and expand treatment choices for patients. Lundbeck / Otsuka’s Rexulti became the first FDA-approved option to treat agitation in AD, and other novel therapies (Otsuka’s AVP-786, Axsome’s Auvelity) are advancing. Understanding neurologists’ preferences and expectations for new therapeutics and payers’ receptivity to high-priced brands in this underserved and heavily generic market is key for developers of agents in the large AD pipeline.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment. Each report includes up-to-date analyses of drug coverage and restriction policies as well as payer and prescriber perspectives on key marketed drugs and their receptivity to emerging therapies.
SOLUTION ENHANCEMENT
Access & Reimbursement includes key analyses from Clarivate Real-World Data Product—comprehensive and timely data that provide clarity around the healthcare experiences and activities of hundreds of millions of patients, HCPs, and payers. Analyses include payer mix, percentage of claim rejections for key therapies, and reasons for claim rejection.
Markets covered: United States
Key drugs: Leqembi, Rexulti, Namzaric, Adlarity, donanemab, Auvelity (AXS-05), KarXT